CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Repairing budgeting mistakes starts with mapping spend, prioritizing essentials, and resetting goals. Use a straightforward plan to correct course and build a durable budget.
17,946 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Bitcoin trades near $63,000 as pardon discussions around Sam Bankman-Fried surface in crypto news. A $32 million hack...
A bid for the 2027 budget would cut a job-training program for low-income seniors, potentially eliminating support fo...
Apple unveils rebuilt Siri at WWDC, sending shares on a brisk intraday swing as investors parse the AI strategy. The ...
Tech stocks swung wildly midday as traders dumped riskier names, then rotated into consumer staples and paints. By da...
Reality TV alum and Candy Kittens founder Jamie Laing says content creators will power the next wave of Fortune 500 b...
Tech leaders are shifting in 2026, prompting a clash between QQQ and VGT for access to Big Tech. This report breaks d...
Insider moves often spark questions when a stock rallies. This article examines Nayax's CMO sale during a solid run, ...
May PPI rose 6.5% year over year, signaling headline inflation pressure at wholesale levels. Yet a steady core measur...
Mind tech (mind) 2027 is shaping a new era for investors who seek durable growth in neurotech and digital mental heal...
A quiet, multi-year surge in AI infrastructure, defense modernization, and electrification is boosting a diversified ...
Alphabet’s billion flex is more than just cash. It’s a strategic playbook that powers buybacks, AI investments, and l...